On May 1, 2026, Health Canada approved donanemab for people with mild cognitive impairment or early-stage Alzheimer’s disease, marking an important milestone in dementia treatment in Canada. Donanemab is part of a newer class of therapies designed to slow the progression of Alzheimer’s disease by targeting amyloid plaques, abnormal protein buildups in the brain linked to the condition. 

Clinical studies have shown encouraging results, with people receiving donanemab experiencing a slower decline in memory, thinking, and everyday functioning compared with those given a placebo. Brain imaging also demonstrated a meaningful reduction in amyloid plaques, suggesting the treatment may help address some of the underlying biological changes associated with Alzheimer’s disease, rather than only managing symptoms. 

While the benefits observed are moderate, they represent a meaningful step forward in a field where treatment options have historically been limited. The approval adds a new option for patients and families navigating the early stages of the disease and reflects growing progress in Alzheimer’s research. 

Donanemab is not a cure, but it is seen as part of an evolving shift toward therapies that may help slow disease progression and preserve independence for longer. Ongoing research will continue to refine how best to use this treatment and understand its long-term impact.